Bisof Vesna, Rakusic Zoran, Despot Marija
Department of Oncology, University Hospital Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia,
Eur Arch Otorhinolaryngol. 2015 Jul;272(7):1553-67. doi: 10.1007/s00405-014-3108-1. Epub 2014 Jun 3.
Anaplastic thyroid cancer (ATC) is one of the most deadly cancers in humans. Searching a PubMed database, studies published during the last 20 years, 63 publications dealing with treatment of patients were identified. Cohort studies comprised 6,609 patients with the median age 68 years (range 57-77 years). The median survival was 3.9 months, and 1 year survival, 20%. The median survival of patients treated with multimodal therapy was 10.5 months. There was significant difference in median survival (7.0 vs. 3.8 months; p < 0.05) and 1 year survival (30.5 vs. 16.8 months; p < 0.05) between the patients <68 and 68 or more years old. Clinical trials, both randomized and non-randomized, comprised 205 patients. Unfortunately, considerable improvement in the understanding of the pathogenesis and genetics of the ATC has not yet resulted in the improvement of the outcome of these patients.
间变性甲状腺癌（ATC）是人类最致命的癌症之一。检索PubMed数据库，确定了过去20年发表的研究，其中63篇涉及患者治疗。队列研究包括6609例患者，中位年龄68岁（范围57 - 77岁）。中位生存期为3.9个月，1年生存率为20%。接受多模式治疗的患者中位生存期为10.5个月。年龄小于68岁和68岁及以上患者的中位生存期（7.0 vs. 3.8个月；p < 0.05）和1年生存率（30.５ vs. 16.8个月；p < 0.05）存在显著差异。临床试验，包括随机和非随机试验，共205例患者。不幸的是，尽管对ATC的发病机制和遗传学有了相当大的认识进展，但这些患者的治疗结果仍未得到改善。
